205 related articles for article (PubMed ID: 36282929)
1. Trends in add-on medications following metformin monotherapy for type 2 diabetes.
Swart EC; Neilson LM; Munshi KD; Peasah SK; Henderson R; Good CB
J Manag Care Spec Pharm; 2022 Nov; 28(11):1253-1259. PubMed ID: 36282929
[No Abstract] [Full Text] [Related]
2. Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations.
Ogunsanmi DO; Harrison AT; Pakker AR; Kovesdy CP; Bailey JE; Surbhi S
J Manag Care Spec Pharm; 2023 Jun; 29(6):699-711. PubMed ID: 37276038
[No Abstract] [Full Text] [Related]
3. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
McCoy RG; Van Houten HK; Deng Y; Mandic PK; Ross JS; Montori VM; Shah ND
JAMA Netw Open; 2021 Feb; 4(2):e2035792. PubMed ID: 33523188
[TBL] [Abstract][Full Text] [Related]
4. Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study.
Newman TV; Munshi KD; Neilson LM; Good CB; Swart ECS; Huang Y; Henderson R; Parekh N
J Manag Care Spec Pharm; 2021 Apr; 27(4):435-443. PubMed ID: 33769857
[No Abstract] [Full Text] [Related]
5. Trends in Prescribing Preferences for Antidiabetic Medications Among Patients With Type 2 Diabetes in the U.K. With and Without Chronic Kidney Disease, 2006-2020.
Liaw J; Harhay M; Setoguchi S; Gerhard T; Dave CV
Diabetes Care; 2022 Oct; 45(10):2316-2325. PubMed ID: 35984049
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
7. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes.
O'Brien MJ; Karam SL; Wallia A; Kang RH; Cooper AJ; Lancki N; Moran MR; Liss DT; Prospect TA; Ackermann RT
JAMA Netw Open; 2018 Dec; 1(8):e186125. PubMed ID: 30646315
[TBL] [Abstract][Full Text] [Related]
8. Changing Patterns of Antihyperglycaemic Treatment among Patients with Type 2 Diabetes in Hungary between 2015 and 2020-Nationwide Data from a Register-Based Analysis.
Jermendy G; Kiss Z; Rokszin G; Abonyi-Tóth Z; Lengyel C; Kempler P; Wittmann I
Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295543
[TBL] [Abstract][Full Text] [Related]
9. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
Vashisht R; Jung K; Schuler A; Banda JM; Park RW; Jin S; Li L; Dudley JT; Johnson KW; Shervey MM; Xu H; Wu Y; Natrajan K; Hripcsak G; Jin P; Van Zandt M; Reckard A; Reich CG; Weaver J; Schuemie MJ; Ryan PB; Callahan A; Shah NH
JAMA Netw Open; 2018 Aug; 1(4):e181755. PubMed ID: 30646124
[TBL] [Abstract][Full Text] [Related]
10. Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study.
Koye DN; Montvida O; Paul SK
Drugs; 2020 Apr; 80(5):477-487. PubMed ID: 32141024
[TBL] [Abstract][Full Text] [Related]
11. Factors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries.
Heintjes EM; Overbeek JA; Hall GC; Prieto-Alhambra D; Lapi F; Hammar N; Bezemer ID
Clin Ther; 2017 Nov; 39(11):2296-2310.e14. PubMed ID: 29108837
[TBL] [Abstract][Full Text] [Related]
12. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of anti-diabetic medications as add-on to metformin in type 2 diabetes mellitus from a real-world database.
Ono R; Ogami C; Hasegawa C; To H; Matsumoto Y; Tsuji Y
BMC Pharmacol Toxicol; 2023 Dec; 24(1):75. PubMed ID: 38066653
[TBL] [Abstract][Full Text] [Related]
14. Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study.
Rathmann W; Bongaerts B; Kostev K
Diabetes Obes Metab; 2016 Aug; 18(8):840-3. PubMed ID: 27062643
[TBL] [Abstract][Full Text] [Related]
15. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
[TBL] [Abstract][Full Text] [Related]
16. Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States.
Sangha V; Lipska K; Lin Z; Inzucchi SE; McGuire DK; Krumholz HM; Khera R
Circ Cardiovasc Qual Outcomes; 2021 Dec; 14(12):e008381. PubMed ID: 34779654
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
[TBL] [Abstract][Full Text] [Related]
18. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes.
Montvida O; Shaw J; Atherton JJ; Stringer F; Paul SK
Diabetes Care; 2018 Jan; 41(1):69-78. PubMed ID: 29109299
[TBL] [Abstract][Full Text] [Related]
19. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications.
Desai NR; Shrank WH; Fischer MA; Avorn J; Liberman JN; Schneeweiss S; Pakes J; Brennan TA; Choudhry NK
Am J Med; 2012 Mar; 125(3):302.e1-7. PubMed ID: 22340932
[TBL] [Abstract][Full Text] [Related]
20. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
Montvida O; Shaw JE; Blonde L; Paul SK
Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]